These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 27644192)

  • 41. Compounded pimobendan for canine chronic degenerative mitral valve disease and pulmonary hypertension.
    Helms SR; Fox S; Mixon W; Vail J
    Int J Pharm Compd; 2012; 16(1):34-41. PubMed ID: 23050309
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study.
    Schober KE; Rush JE; Luis Fuentes V; Glaus T; Summerfield NJ; Wright K; Lehmkuhl L; Wess G; Sayer MP; Loureiro J; MacGregor J; Mohren N
    J Vet Intern Med; 2021 Mar; 35(2):789-800. PubMed ID: 33543810
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group.
    Ettinger SJ; Benitz AM; Ericsson GF; Cifelli S; Jernigan AD; Longhofer SL; Trimboli W; Hanson PD
    J Am Vet Med Assoc; 1998 Dec; 213(11):1573-7. PubMed ID: 9838955
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Atrial Fibrillation as a Prognostic Indicator in Medium to Large-Sized Dogs with Myxomatous Mitral Valvular Degeneration and Congestive Heart Failure.
    Jung SW; Sun W; Griffiths LG; Kittleson MD
    J Vet Intern Med; 2016; 30(1):51-7. PubMed ID: 26681398
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Acute and short-term hemodynamic, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: results of the Invasive Multicenter PROspective Veterinary Evaluation of Enalapril study. The IMPROVE Study Group.
    J Vet Intern Med; 1995; 9(4):234-42. PubMed ID: 8523320
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Short-term effects of atorvastatin in normal dogs and dogs with congestive heart failure due to myxomatous mitral valve disease.
    Cunningham SM; Rush JE; Freeman LM
    J Vet Intern Med; 2013; 27(4):985-9. PubMed ID: 23758137
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Controlled clinical evaluation of enalapril in dogs with heart failure: results of the Cooperative Veterinary Enalapril Study Group. The COVE Study Group.
    J Vet Intern Med; 1995; 9(4):243-52. PubMed ID: 8523321
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Canine degenerative myxomatous mitral valve disease: natural history, clinical presentation and therapy.
    Borgarelli M; Haggstrom J
    Vet Clin North Am Small Anim Pract; 2010 Jul; 40(4):651-63. PubMed ID: 20610017
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of pimobendan in the management of heart failure.
    Fuentes VL
    Vet Clin North Am Small Anim Pract; 2004 Sep; 34(5):1145-55. PubMed ID: 15325474
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An update on treatment and prognostic indicators in canine myxomatous mitral valve disease.
    Häggström J; Höglund K; Borgarelli M
    J Small Anim Pract; 2009 Sep; 50 Suppl 1():25-33. PubMed ID: 19765217
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Partial external mitral annuloplasty in dogs with myxomatous mitral valve degeneration and congestive heart failure: outcome in 9 cases.
    de Andrade JN; Christopher Orton E; Boon J; Nishimori CT; Olivaes C; Camacho AA
    J Vet Cardiol; 2011 Sep; 13(3):197-201. PubMed ID: 21824833
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Improvement of cardiac performance by pimobendan, a new cardiotonic drug, in the experimental failing dog heart.
    Satoh K; Satoh Y; Imagawa J; Taira N
    Jpn Heart J; 1993 Mar; 34(2):213-9. PubMed ID: 8315818
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease.
    McManamey AK; DeFrancesco TC; Meurs KM; Papich MG
    J Vet Intern Med; 2023; 37(6):2003-2010. PubMed ID: 37776546
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Concerns about "Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease".
    Corcoran B; Culshaw G; Dukes-McEwan J; French A; Smith S; Swift S
    J Vet Intern Med; 2008; 22(2):243; author reply 245. PubMed ID: 18371020
    [No Abstract]   [Full Text] [Related]  

  • 55. Increased NT-proANP predicts risk of congestive heart failure in Cavalier King Charles spaniels with mitral regurgitation caused by myxomatous valve disease.
    Eriksson AS; Häggström J; Pedersen HD; Hansson K; Järvinen AK; Haukka J; Kvart C
    J Vet Cardiol; 2014 Sep; 16(3):141-54. PubMed ID: 25130405
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predictors of reoccurrence of congestive signs within 180 days after successful treatment of the first episode of congestive heart failure in dogs with myxomatous mitral valve disease.
    Franchini A; Abbott JA; Tyrrell W; Rosenthal S; Lahmers S; Menciotti G; Crosara S; Häggström J; Borgarelli M
    J Vet Cardiol; 2021 Apr; 34():112-119. PubMed ID: 33706221
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease.
    Sarcinella F; Neves J; Maddox TW; Hodgkiss-Geere HM; Bode EF; Dukes-McEwan J
    Open Vet J; 2020 Jan; 9(4):375-383. PubMed ID: 32042661
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tissue Doppler and strain imaging in dogs with myxomatous mitral valve disease in different stages of congestive heart failure.
    Tidholm A; Ljungvall I; Höglund K; Westling AB; Häggström J
    J Vet Intern Med; 2009; 23(6):1197-207. PubMed ID: 19909428
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multiple retrospective analysis of survival and evaluation of cardiac death predictors in a population of dogs affected by degenerative mitral valve disease in ACVIM class C treated with different therapeutic protocols.
    Bagardi M; Locatelli C; Zanaboni A; Galizzi A; Malchiodi D; Brambilla PG
    Pol J Vet Sci; 2021 Mar; 24(1):109-118. PubMed ID: 33847106
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Concerns about "Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded and randomized study".
    Le Bobinnec G
    J Vet Intern Med; 2008; 22(2):243-4; author reply 245-6. PubMed ID: 18371019
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.